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Abstract
Background: The prognosis for adult patients with Ph(-) B-precursor acute lymphoblastic leukaemia (ALL) who
are refractory to treatment or experience relapse (R/R), is poor; over 90 % of these patients die from the disease,
typically within a few months. While there are some national guidelines published for the treatment of adult
patients with ALL, and local working group recommendations do exist, there is very little detail and no preferred
treatment regimens for adult patients with R/R Ph(-) B-precursor ALL. The aim of this study was to describe
current real-world clinical practice in Europe for the management and treatment of adult R/R Ph(–) B-precursor ALL.
Methods: A web-based, double-blind survey was conducted in November/December 2013 in France, Germany, Italy,
Spain, and the UK. The survey was developed following consultation with specialist clinicians and a critical review of
published literature. Eligible clinicians (15 per country) were board-certified in haemato-oncology or haematology; had
at least 4 years of experience in their current role and had treated at least five patients with adult ALL in the 36 months
before the survey, including at least one with R/R Ph(−) B-precursor ALL.
Results: Clinicians across the five countries consulted 16 guidelines and local working group recommendations for the
diagnosis and treatment of R/R Ph(–) B-precursor ALL. Thirty three regimens for salvage therapy were reported;
the most frequently cited was augmented hyper-CVAD (15 %), with vincristine the most commonly used agent.
Salvage therapy regimens involved a range of agents, and most respondents reported using at least one cytotoxic
agent; across respondents 10 different cytotoxic agents were cited. All respondents reported that toxicity was common
for the regimens they used to treat R/R Ph(–) B-precursor ALL.
Conclusions: This study provides evidence of current management and treatment patterns of R/R Ph(–) B-precursor
ALL in the real-world clinical practice in Europe. The approach to the treatment of R/R Ph(–) B-precursor ALL is
heterogeneous, reflecting the lack of any clearly superior chemotherapeutic option, thus it appears that clinicians
are trying a wide variety of therapies. These findings show a clear need for effective, tolerable treatments for R/R
Ph(–) B-precursor ALL.
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Background
Acute lymphoblastic leukemia (ALL) is a rare disease
with an incidence of 1.2–1.4 per 100,000 population per
year in Europe [1]. It is an aggressive malignancy, char-
acterised by a sudden onset and rapid progression, and
diagnosis usually requires urgent medical attention [2–
4]. ALL encompasses several subtypes that are classified
according to cell lineage (T- or B-cell), cell type (mature or
precursor), and the presence or absence of the Philadel-
phia (Ph) chromosome translocation – Ph(+) or Ph(−).
The prognosis for adult patients with Ph(−) B-precursor
ALL who are refractory to treatment or experience relapse
is poor [5–9]. In a study incorporating all subtypes of ALL,
≥90 % of those with Ph(−) disease and those with the
B-precursor immunophenotype died of the disease, with a
5 year overall survival of ≤10 % [10]. Median overall
survival after a diagnosis of relapsed or refractory (R/R)
disease is less than 6 months [9–12]. Unfortunately,
progress in the development of treatments for Ph(−)
B-precursor ALL has been slow, with scarce innovative
treatments having been approved in the EU for adult
patients in decades. Because of the lack of innovative
treatment options, the only options for most patients
are salvage therapy regimens and recourse to a wide range
of chemotherapies used in combination, including cortico-
steroids, alkylating agents, anthracyclines and cytotoxic
antibiotics, antimetabolites, vinca alkaloids, and asparagi-
nase [5, 9]. The small percentage of patients who respond
to salvage therapy, may have an option to receive allogen-
eic haematopoietic stem cell transplant (HSCT), which is
currently the only potentially curative option for adult
patients with R/R B-precursor ALL [13].
While there are some national and international guide-
lines published for treatment of adult patients with ALL
(eg, NCCN 2014 [9]), there is very little detail and no
preferred treatment regimens for adult patients with R/R
Ph(−) B-precursor ALL. The guidelines list options for
R/R Ph(−) B-precursor ALL, but do not recommend any
one treatment over another. Although there are no Eur-
ope-wide clinical practice guidelines, recommendations
have been proposed by the European Working Group for
Adult Acute Lymphoblastic Leukemia (EWALL) [5]; but
again, there is very little specific information about the
treatment of adult R/R Ph(−) B-precursor ALL. In some
countries, clinicians use treatment protocols developed by
their respective national study groups for guidance, which
may provide more specific information about the treatment
of adult patients with R/R Ph(−) B-precursor ALL.
The literature and treatment guidelines acknowledge
many options, however, there are no journal articles
describing real-world treatment patterns. Therefore,
the aim of this clinician survey was to describe current
real-world clinical practice for the management – including
diagnosis, response definition and HSCT eligibility – and
treatment of R/R Ph(–) B-precursor ALL in five European
countries (France, Germany, Italy, Spain, and the UK).
Methods
A cross-sectional, web-based, double-blind survey of
clinicians who specialise in the treatment of adults with
ALL was conducted over an 8-week period in November/
December 2013. The survey aimed to yield information
on the diagnosis and treatment of patients with R/R Ph(–)
B-precursor ALL in France, Germany, Italy, Spain, and the
UK. Ethics approval was granted by the Human Research
Ethics Committee of the University of Technology, Sydney
and all participants provided informed consent before
starting the survey. Eligible participants were compensated
for their time (at the fair market value), provided this was
allowed by local legislation and guidelines.
Survey development
The survey was a structured questionnaire that was de-
veloped in three distinct and iterative steps [14].
Questionnaire development
The content of the questionnaire was informed by a critical
review of clinical guidelines, treatment protocols for ALL,
published papers on treatment practices in ALL, and
systematic reviews of safety and efficacy studies [9, 15–33].
Haematologists and haemato-oncologists were then
consulted to advise on the content. The questionnaire
consisted mainly of multiple-choice questions with a
few open-ended questions, and covered the following
topics for R/R Ph(–) B-precursor ALL: demographics
of responders; diagnosis; salvage therapy; evaluation of
response; and use of HSCT. Please see abbreviated version
of questionnaire as an additional file (Additional file 1).
Questionnaire validity
The questionnaire was pre-tested by haemato-oncologists
from France, Germany and the UK to ensure the questions
were relevant, comprehensible and unambiguous. A pilot
questionnaire was then created based on the feedback
received on the validity of the questionnaire and on input
from a medical statistician.
Pilot study
The pilot study was conducted to confirm that the ques-
tionnaire was easily understood, and well targeted, and
that it provided informative results. One participant was
recruited per country, except for Germany where two
participants were recruited, because Germany has the
largest clinician population.
The pilot questionnaire was administered in the local
language; the accuracy of translations was confirmed
using back-translations. The web-based questionnaire was
followed by a telephone interview in English to obtain
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feedback on the face validity, comprehensiveness, length,
clarity, flow, ease of use, and design of the web interface of
the questionnaire; the appropriateness of the clinical as-
pects of the questions and the accuracy of the translations
were also assessed. Feedback from the pilot questionnaire
was used to refine the questionnaire for the survey. Results
from the pilot study were not included in the survey re-
sults and participants who were included in the pilot study
were not included in the survey.
Survey conduct
Eligible participants (15 per country) completed the web-
based questionnaire at their own pace and in the local lan-
guage. Participants were able to withdraw from the survey
at any time and for any reason and were replaced with
other eligible participants from the same country who met
the eligibility criteria. Data from incomplete surveys were
not used in the final analysis.
Participant recruitment
Participants from France, Germany, Italy, Spain, and the
UK were recruited from sampling lists. The lists were
provided by a commercial agency with an established
panel of practicing clinicians who treat adult ALL and
have agreed to participate in such studies; the agency
identified potential clinicians primarily through publica-
tions and attendance at conferences. Within each coun-
try, clinicians with the most experience of treating ALL
were contacted first; contact and screening of potential
clinicians continued until the planned number of eligible
clinicians had completed the survey. An initial e-mail
invitation was sent to clinicians explaining the objective
of the study and a screener questionnaire then followed
to determine clinicians’ eligibility to participate in the
survey. Eligible participants were those who were board-
certified in haemato-oncology or haematology; had at least
4 years’ experience in their current role (or similar role at
another institution) and had treated at least five patients
with adult ALL in the 36 months before the survey, in-
cluding at least one patient with B-cell ALL, one with
precursor B-cell ALL, one with Ph(-) B-precursor ALL
and one with R/R Ph(–) B-precursor ALL.
The planned sample size of 15 participants per country
was based on previous experience of working with this
group of clinicians and the relatively small number of
clinicians who treat patients with this disease. Although
more than 100 oncologists and haemato-oncologists are
registered with the agency for each country, the survey
focused on a subgroup of patients with a rare disease,
the screening criteria were restrictive, and the typical re-
sponse rate for such surveys is 30 %; thus, 15 participants
per country was expected to be achievable. Regional quotas
were applied within each country based on the distribution
of the general population.
Statistical analysis
The survey was a descriptive study, and no formal statistical
hypotheses were tested. Descriptive statistics were used to
summarise findings and to enumerate the common regi-
mens prescribed by clinicians who treat patients with R/R
Ph(–) B-precursor ALL. Percentage and number of respon-
dents were used to describe categorical variables. Mean and
median were used to describe continuous variables. For
some questions respondents could select multiple criteria
resulting in statistics that were not mutually exclusive. De-
identified datasets from the survey were used to analyse the
results for each country separately; when appropriate, the
results from the five countries were then aggregated.
The analyses were performed by a statistician using SAS
statistical package version 9.3 (Cary, NC), according to a
pre-specified statistical analysis plan.
Results
Demographics of responders
A total of 187 clinicians were contacted (France, n = 38;
Germany, n = 28; Italy, n = 50; Spain, n = 32; UK, n = 39);
of these, 23 were not eligible because they did not meet
the screening criteria, either because they did not treat
haematological malignancies frequently; had not treated
enough patients in the last 36 months; or had <4 years’
experience in treating ALL (France, n = 3; Germany, n = 1;
Italy, n = 8; Spain, n = 2; UK, n = 9). Of those who were
eligible (n = 164), 75 clinicians across the five countries
completed the survey (overall completion rate for eligible
clinicians, 46 %; completion rates per country: France,
43 %; Germany, 56 %; Italy, 36 %; Spain, 50 %; UK, 50 %).
Most respondents worked at university hospitals (64 %,
n = 48) or at cancer hospitals/specialist oncology cen-
tres/specialist haematology centres (23 %, n = 17). The
demographics of those clinicians who were eligible and
who completed the survey (n = 15, per country) are shown
in Table 1.
Diagnosis of R/R Ph(–) B-precursor ALL
The clinical criteria used to define relapsed or refractory
disease were similar across the countries. For relapsed
disease the most frequently reported clinical criteria
were analysis of lymphoblasts in bone marrow (BM) as-
pirate and biopsy (91 %, n = 68) and minimal residual
disease (MRD) by either PCR or flow cytometry (FCM)
(65 %, n = 49). For refractory disease the most frequently
reported clinical criteria were also analysis of lympho-
blasts in BM aspirate and biopsy (89 %, n = 67) and
MRD by either PCR or FCM (69 %, n = 52). Most clini-
cians (73 %, n = 55) consulted treatment guidelines and/
or local working group recommendations for advice on
making a diagnosis of R/R Ph(−) B-precursor ALL, with
10 guidelines and local working group recommendations
cited (Table 2).
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Treatment patterns of R/R Ph(–) B-precursor ALL
Treatment guidelines
Across the five countries, no central guideline for the
treatment of R/R Ph(−) B-precursor ALL is consulted. Most
clinicians consult local working group recommendations
(i.e. the German Multicenter Study Group for Adult ALL
[GMALL]; the Gruppo Italiano Malattie EMatologiche del-
l’Adultodell’Adulto [GIMEMA]; the Program for Study and
Treatment of Malignant Haemopathies, Spanish Society
of Haematology [PETHEMA], and the guidelines of the
Medical research Council ALL Trials XII [UKALL XII])
(Table 3). However, more than half of the clinicians refer
to American Society of Hematology/American Society of
Clinical Oncology [ASH/ASCO] guidelines, in addition to
their local working group recommendations. EWALL and
National Comprehensive Cancer Network (NCCN) guide-
lines were also frequently consulted. In total 16 guidelines
and/or local working group recommendations were cited
(Table 3).
Salvage therapy
Across the five countries, a range of salvage therapy
regimens were reported by clinicians for the treatment
of R/R Ph(−) B-precursor ALL; of 33 reported regimens,
augmented hyper-CVAD (hyperfractionated-cyclophospha-
mide, vincristine, doxorubicin, dexamethasone) was the
most frequently reported (15 %, n = 11), followed by FLAG-
IDA (fludarabine, high-dose cytarabine-idarubicin) (12 %,
Table 1 Demographics of respondents in each country (N = 15 per country)
France Germany Italy Spain UK Total
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
Speciality, n (%)
Oncologist 5 (33) 1 (7) 3 (20) 0 (0) 0 (0) 9 (12)
Haematologist 5 (33) 2 (13) 7 (47) 8 (53) 8 (53) 30 (40)
Haemato-oncologist 5 (33) 12 (80) 5 (33) 7 (47) 7 (47) 36 (48)
Location, n (%)
University hospital 7 (47) 10 (67) 7 (47) 13 (86) 11 (73) 48 (64)
Cancer hospital/specialist centre 6 (40) 4 (27) 5 (33) 0 (0) 2 (13) 17 (23)
Community/urban/general hospital 2 (13) 1 (7) 3 (20) 2 (13) 2 (13) 10 (13)
Experience, years
Years treating adults with ALL, median (range) 15 (7–29) 12 (8–18) 10 (6–30) 16 (9–34) 12 (17–20) N/A
Caseloada of ALL subtypes from 12 months before the survey, n
ALL, median (range) 30 (3–200) 20 (6–100) 30 (5–100) 20 (3–230) 24 (4–200) N/A
R/R Ph(–) B-precursor ALL, median (range) 8 (1–75) 3 (1–21) 5 (1–50) 4 (0–55) 4 (1–50) N/A
aNumber of patients
ALL acute lymphoblastic leukaemia, N/A not available, Ph(–) Philadelphia negative, R/R relapsed or refractory
Table 2 Guidelines/local working group recommendations consulted for diagnosis of relapsed or refractory Ph(–) B-precursor ALL
Guideline or local working group recommendation Number of respondents consulting for diagnosis, n (%)a
France Germany Italy Spain UK Total
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
ASH/ASCO, US 6 (40) 2 (13) 10 (67) 5 (33) 3 (20) 26 (35)
EWALL, Europe 6 (40) 1 (7) 3 (20) 2 (13) 4 (27) 16 (21)
NCCN, US 3 (20) 7 (47) 4 (27) 14 (19)
GMALL, Germany 1 (7) 8 (53) 1 (7) 1 (7) 11 (15)
GIMEMA, Italy 10 (67) 10 (13)
PETHEMA, Spain 9 (60) 9 (12)
Othersb 3 (20) 1 (7) 4 (5)
aRespondents could select multiple guidelines bThe following guidelines and/or local working group recommendations were consulted by one respondent for
diagnosis: HAS, France; Onco LR, France; GELA, France; BCSH, UK
ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for
Standards in Haematology; EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte (Study Group
of the Adult Lymphoma); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL,
German Multicenter Study Group for Adult ALL; HAS, Haute Autorité de Santé (High Authority for Health); NCCN, the National Comprehensive Cancer Network;
Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and
Treatment of Malignant Haemopathies, Spanish Society of Haematology
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n = 9) and GMALL 07/03 (9 %, n = 7) (Table 4). The
majority of clinicians reported using published regimens
of salvage therapy (81 %, n = 61); a smaller number of
respondents reported using modified versions of
published regimens (16 %, n = 12). Few respondents
(3 %, n = 2) used regimens from ongoing clinical trials.
The reported regimens consist of a range of agents.
Cyclophosphamide, vincristine, prednisone and L-
asparaginase were frequent components of the pub-
lished regimens. Of the agents reported by clinicians
across all regimens (published and modified), vincris-
tine was the most commonly reported (61 %, n = 46)
followed by L-asparaginase (49 %, n = 37). The use of at
least one cytotoxic agent was reported by most
respondents, particularly anthracyclines (88 %, n = 64);
other agents included immunosuppressor/anti-inflam-
matory agents (i.e. dexamethasone and predniso(lo)ne;
68 %, n = 50), agents for the reduction of side effects
(i.e. granulocyte-colony stimulating factor and folinic
acid; 70 %, n = 51), additional central nervous system
prophylaxis (66 %, n = 48), and the immunotherapy agent
inotuzumab ozogamicin (1 %, n = 1). Most clinicians
(70 %, n = 51) reported using one course of salvage ther-
apy, although some (19 %, n = 14) also used a preparatory
course and/or a second course (23 %, n = 17). When
reporting the agents used for salvage therapy, two respon-
dents were excluded as their description of the regimen
used did not match the agents they had reported using
(France, n = 1; UK, n = 1).
Adverse events
All respondents reported that treatment- or disease-re-
lated toxicities were common. Cytopenia, infection and
mucositis were reported to be the most frequent adverse
events (AEs) by most respondents (91 %, 85 %, 76 % of
clinians reported the AE as common, respectively). Other
AEs reported to be quite frequent were pyrexia, fatigue,
bleeding, neuropathy, cardiac toxicity and hepatopathy.
Cyclophosphamide and high-dose cytarabine were among
the individual agents most commonly reported to cause
AEs (50 % and 36 % of all reported agents, respectively).
Assessment of response to salvage therapy
Assessment of response after completion of therapy was
typically done after a median of 30-days (range: 2–180-
days). The most commonly reported tests to evaluate
response were complete blood count (85 %, n = 64),
BM aspirate followed by FCM immunophenotyping
(75 %, n = 56) and physical examination (72 %, n = 54).
Other tests used by more than half of respondents were
peripheral blood differential count (69 %, n = 52), BM
aspirate/biopsy followed by cell morphology analysis
(61 %, n = 46), peripheral blood smear (60 %, n = 45)
and MRD by PCR (59 %, n = 44).
Table 3 Guidelines/local working group recommendations consulted for treatment of relapsed or refractory Ph(–) B-precursor ALL
Guideline or local working group recommendation Number of respondents consulting for treatment n (%)a
France Germany Italy Spain UK Total
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
ASH/ASCO, US 9 (60) 3 (20) 7 (47) 6 (40) 4 (27) 29 (39)
EWALL, Europe 7 (47) 1 (7) 2 (13) 2 (13) 7 (47) 19 (25)
NCCN, US 6 (40) 1 (7) 5 (33) 5 (33) 17 (23)
GMALL, Germany 1 (7) 13 (60) 1 (7) 1 (7) 16 (21)
GIMEMA, Italy 12 (80) 1 (7) 13 (17)
PETHEMA, Spain 11 (73) 1 (7) 12 (16)
UKALL XII, UK 1 (7) 11 (73) 12 (16)
HAS, France 2 (13) 2 (3)
Othersb 4 (27) 3 (20) 7 (9)
aRespondents could select multiple guidelines
bThe following guidelines and/or local working group recommendations were consulted by one respondent for treatment: COOPRALL, France; Onco LR, France;
GELA, France; GRAALL, France; BCSH, UK; The Beatson hospital, UKc; UKALL 2011 for young adults, UK; non-specified protocol
cThe Beatson hospital is a cancer centre located in the West of Scotland
ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for
Standards in Haematology; COOPRALL, Protocole Coopérateur de Traitement des Rechutes de Leucémies Aiguës Lymphoblastiques de L’enfant (treatment
protocol for relapse of ALL in children); EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte
(Study Group of the Adult Lymphoma); GET-LALA, Groupe d’Etude et de Traitement des Leucémie Aiguës Lymphoblastique de l’Adulte (Group for the Study and
Treatment of Adult ALL, France); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults);
GMALL, German Multicenter Study Group for Adult ALL; GOELAMS, Groupe Ouest Est des Leucémies Aiguës et Maladies du Sang (East West Group of Acute
Leukemia and Blood Diseases, France); GRAALL, Cooperative group combining the French GET-LALA, the GOELAMS, and the SAKK; HAS, Haute Autorité de Santé
(High Authority for Health); NCCN, the National Comprehensive Cancer Network; Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional
network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and Treatment of Malignant Haemopathies, Spanish Society of Haematology; SAKK,
Schweizer Arbeitsgemeinschaft für klinische Krebsforschung, Leukämie-Arbeitsgruppe (Swiss Group for Clinical Cancer Research, Leukemia Working Group); UKALL
2011 for young adults, United Kingdom Trial for children and young adults with Acute lymphoblastic Leukaemia and Lymphoma 2011; UKALL XII, Medical Re-
search Council Acute Lymphoblastic Leukemia Trial XII
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Complete remission
The most frequently chosen criterion to define CR was
the level of lymphoblasts in BM (87 %, n = 65). Absence
of circulating lymphoblasts (77 %, n = 58), absence of
extramedullary disease (75 %, n = 56), and MRD using
either PCR or FCM (69 %, n = 52) were also reported
by more than 50 respondents. Most respondents (69 %,
n = 52) considered CR to have been achieved if the rele-
vant criteria were met at a time point after completion
of treatment, regardless of how long the response was
maintained, whereas some respondents (11 %, n = 8) re-
quired the response to be maintained for a specific time
from completion of treatment. Other respondents re-
quired the response to be maintained from completion
of treatment throughout further therapy (20 %, n = 15).
Eligibility for HSCT after salvage therapy
Most respondents (76 %, n = 57) reported that HSCT
could be performed at their centre. Over the 36 months
before the clinician survey, almost half of the respondents’
patients were deemed eligible for HSCT (48 %), and 42 %
received HSCT.
The most frequently chosen criterion to determine
eligibility for HSCT was the level of lymphoblasts in
BM (81 %, n = 61). Most respondents (63 %, n = 47)
considered a patient to be eligible for HSCT if the relevant
criteria were met at a time point after completion of treat-
ment, regardless of how long the response was maintained,
whereas some respondents (12 %, n = 9) required the
response to be maintained for a specific time from
completion of treatment (range: 21 days to 12 months).
Other respondents required the response to be maintained
from completion of treatment throughout further therapy
(25 %, n = 19).
Discussion
To our knowledge, this is the first study to explore the
real-world clinical practice for adult R/R Ph(–) B-
precursor ALL in Europe. The results of this survey
have shown that the approach to the management and
treatment of R/R Ph(−) B-precursor ALL is heterogeneous.
Across the five countries, 16 guidelines and local working
group recommendations were consulted for the diagnosis
and treatment of R/R Ph(–) B-precursor ALL.
Table 4 Regimens used for salvage therapy, per country
Regimen Number of respondents, na,b
France Germany Italy Spain UK Total, n (%)
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
Published regimens
Augmented hyper-CVAD 3 1 2 5 11 (15)
CALGB 8811/Larson 1 1 1 3 (4)
EORTC ALL-3 (induction phase) 1 2 3 (4)
FLAG-AMSA 1 1 2 (3)
FLAG-IDA 1 2 6 9 (12)
GMALL 07/03 6 1 7 (9)
GRAALL 02/2005 (salvage phase) 2 1 3 (4)
GRAALL 2003 (salvage phase) 1 2 3 (4)
Hyper-CVAD 1 1 1 1 4 (5)
MRC UK ALL XII/ECOG 2993 1 3 4 (5)
PETHEMA ALL-96 2 2 (3)
Modified published regimens
FLAG-IDA 1 2 3 (4)
aRespondents could select multiple guidelines regimens
bPublished regimens reported by one respondent were: EORTC ALL3 (salvage); GIMEMA 0288 (induction phase); GIMEMA 0288 (salvage); GIMEMA-LAL0904 (induction phase);
GIMEMA-LAL0904 (salvage); GRAALL 02/2005 (induction phase); LALA-94; nelarabine/cyclophosphamide; PALG 5–2007 (Induction II); VANDEVOL; modified
published regimens reported by one respondent were: aBFM; augmented hyper-CVAD; CALGB 8811/Larson; GRAALL 02/2005 (induction phase); LALA-94; MRC
UK ALL XII/ECOG 2993; PETHEMA ALL-96; RWGALS – NP1 (Induction I); VANDEVOL; ongoing clinical trials reported by one respondent were: NCT01564784 and
UKALL 2011 trial
aBFM, augmented Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukaemia; CALGB, Cancer and Leukemia Group B; CVAD, cyclophosphamide, vincristine,
doxorubicin (Adriamycin), dexamethasone; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer;
FLAG-AMSA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-amsacrine; FLAG-IDA, fludarabine, high-dose cytarabine, granulocyte colony-
stimulating factor-idarubicin; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German
Multicenter Study Group for Adult ALL; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; LALA, Leucémie Aiguës Lymphoblastique de l’Adulte
(Acute Lymphoblastic Leukemia in Adults); MRC UKALL XII, Medical Research Council Acute Lymphoblastic Leukemia Trial XII; PALG, Polish Adult Leukemia Group;
PETHEMA, Programa para el Estudio de la Terapéutica en Hemopatía Maligna (Program for Study and Treatment of Malignant Hemopathies); RWGALS-NP1, Romanian
Working Group for Acute Leukemia Study National Protocol 1; VANDEVOL, etoposide, clofarabine, asparaginase, mitoxantrone, and dexamethasone
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Clinicians reported the use of 33 regimens for salvage
therapy with augmented hyper-CVAD the most fre-
quently reported (15 %). Salvage therapy consisted of
10 different cytotoxic agents, with the use of at least
one cytotoxic agent reported by most respondents.
The existence of so many regimens is likely to reflect
the lack of a clearly superior chemotherapeutic option
for the treatment of R/R Ph(–) B-precursor ALL. With
no superior option available, it appears that clinicians
who treat these patients are trying a wide variety of ther-
apies to treat the disease, with it likely that treatment de-
cisions may be impacted by access to certain drugs and
patient-related factors (i.e. age and comorbidities), in
addition to clinical efficacy. Of interest, few clinicians
treat their patients within clinical trials which may re-
flect the scarcity of new agents and potential difficulty to
access clinical trials. Although only 10 different cytotoxic
agents were reported, the wide variety of regimens
reflected different combinations, dosings, and dosing
intervals of these agents, which further reflect the lack
of a treatment consensus for treatment of R/R Ph(–)
B-precursor ALL.
The reported timing of the assessment of response to
salvage therapy also varied widely; although the median
is 30 days, clinicians reported up to 180 days. It is postu-
lated that these clinicians might be looking for a durable
response to salvage therapy, thus the extended period
prior to assessment. Similiarly, it is likely that clinicians
were also looking for a durable response when considering
their patient’s eligibility for HSCT, hence the wide range
reported for maintenance of response from completion of
treatment (range: 21 days to 12 months).
In addition to being the first study to explore the real-
world clinical practice for adult R/R Ph(−) B-precursor
ALL in Europe, there are several strengths in this study.
First is the robust method of survey development. To
develop the survey, a thorough review of guidelines and
of the literature was conducted, as well as obtaining clin-
ician input. We then conducted pre-testing and a pilot
survey to ensure the validity of the survey. Second, we
pre-specified the number of respondents for each coun-
try, to make sure the data we collected were representa-
tive and accurate. Third, we set up stringent inclusion
criteria for the respondents to ensure the responses were
from those who have extensive experience treating R/R
Ph(−) B-precursor ALL.
There were some potential limitations to the study. The
sampling process aimed to recruit clinicians with the most
experience, and most were from specialist centres, such as
university hospitals and cancer hospitals. However, not all
eligible clinicians accepted the invitation to participate in
the survey. For this reason, there is a potential for bias in
the responses. Regarding sample size, although the pre-
specified number of responders may be considered small
(n = 15), given the rarity of the disease and the stringent
inclusion criteria requiring clinicians to have treated a cer-
tain amount of ALL patients, the sample size is considered
adequate.
Conclusion
This study provides evidence of current management
and treatment patterns of R/R Ph(–) B-precursor ALL in
the real-world clinical practice. There is a lack of consen-
sus and treatment for adults with this disease varies widely
across Europe. The existence of so many regimens reflects
the lack of a clearly superior chemotherapeutic option for
the treatment of R/R Ph(–) B-precursor ALL; thus it ap-
pears that clinicians are trying a wide variety of therapies.
These finding show a clear need for effective, tolerable
treatments for R/R Ph(–) B-precursor ALL.
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